Dulaglutide vs Liraglutide

Both are GLP-1 receptor agonists with cardiovascular-outcome trials (REWIND and LEADER), but dulaglutide is a large Fc-fusion protein dosed weekly and liraglutide a small acylated peptide dosed daily.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Dulaglutide

A once-weekly GLP-1 receptor agonist made by fusing two GLP-1 analogues to an antibody Fc fragment.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Liraglutide

A once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analogue developed by acylation, predecessor to semaglutide.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Dulaglutide	Liraglutide
The key difference	Weekly, Fc-fusion	Daily, acylated
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Dulaglutide’s Fc fusion gives it a large size and slow clearance, allowing weekly dosing at the GLP-1 receptor with the class’s glucose-dependent insulin and glucagon effects.	Liraglutide carries a C16 fatty-acid side chain that allows albumin binding and self-association, extending its half-life to about 13 hours.
Status	Approved for type 2 diabetes; the REWIND cardiovascular-outcomes trial is its landmark dataset.	Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa.
Reported safety signals	Class gastrointestinal effects; REWIND exploratory analyses also examined renal and cognitive outcomes.	Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented.
A key study	REWIND measured major adverse cardiovascular events with dulaglutide versus placebo in type 2 diabetes. (Lancet 2019, PMID 31189511)	Traces how acylation strategies extended GLP-1’s half-life, first in liraglutide and then semaglutide. (Front Endocrinol (Lausanne) 2019, PMID 31031702)

WHEN TO RESEARCH WHICH

They are the classic comparison of weekly versus daily GLP-1 agonism. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Dulaglutide] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial — Lancet 2019. PMID 31189511
[Dulaglutide] Dulaglutide: A Review in Type 2 Diabetes — Drugs 2020. PMID 32002850
[Dulaglutide] Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial — Lancet Neurol 2020. PMID 32562683
[Liraglutide] The Discovery and Development of Liraglutide and Semaglutide — Front Endocrinol (Lausanne) 2019. PMID 31031702
[Liraglutide] A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — N Engl J Med 2015. PMID 26132939
[Liraglutide] Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies — J Clin Med 2025. PMID 40507553

FREQUENTLY ASKED

What is the difference between Dulaglutide and Liraglutide?

What is the regulatory status of Dulaglutide and Liraglutide?

Dulaglutide: Approved for type 2 diabetes; the REWIND cardiovascular-outcomes trial is its landmark dataset. Liraglutide: Approved for type 2 diabetes and (at a higher dose) weight management; trialled in adolescents and children. Prescription-only in South Africa.

What safety signals have been reported?

Dulaglutide: Class gastrointestinal effects; REWIND exploratory analyses also examined renal and cognitive outcomes. Liraglutide: Gastrointestinal effects predominate; network meta-analyses compare its efficacy and safety with semaglutide and tirzepatide; weight regain after interruption is documented.

Which studies is this comparison based on?

For Dulaglutide: “Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial” (PMID 31189511); “Dulaglutide: A Review in Type 2 Diabetes” (PMID 32002850); “Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial” (PMID 32562683). For Liraglutide: “The Discovery and Development of Liraglutide and Semaglutide” (PMID 31031702); “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management” (PMID 26132939); “Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies” (PMID 40507553).